Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. 1985

J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008947 Mixed Connective Tissue Disease A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence. Connective Tissue Disease, Mixed,Sharp Syndrome,MCTD,Syndrome, Sharp
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
November 1977, Pharmacological research communications,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
April 1980, Prostaglandins,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
February 1992, American heart journal,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
December 1979, Lancet (London, England),
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
February 1978, Pharmacological research communications,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
April 1988, Thrombosis and haemostasis,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
January 1980, Advances in prostaglandin and thromboxane research,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
February 1986, Thrombosis research,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
May 1987, Journal of the National Cancer Institute,
J Keller, and A Kaltenecker, and K T Schricker, and B Neidhardt, and O P Hornstein
January 1985, Advances in prostaglandin, thromboxane, and leukotriene research,
Copied contents to your clipboard!